en.wikipedia.org website review
Improve your SEO :: free trial!
en.wikipedia.org is 52% geoptimaliseerd!
SEO Keyword summary for en.wikipedia.org/wiki/amivantamab
Keywords are extracted from the main content of your website and are the primary indicator of the words this page could rank for. By frequenty count we expect your focus keyword to be with
Focus keyword
Short and long tail
Short Tail Keywords with from amivantamab |
long Tail Keywords (2 words) may 2021 lung cancer cell lung non-small cell 21 may |
long Tail Keywords (3 words) cell lung cancer non-small cell lung 21 may 2021 drug administration fda egfr exon 20 food and drug may 2021 retrieved |
en.wikipedia.org On-Page SEO Scan
Descriptive Elements
The <head> element of a en.wikipedia.org/wiki/amivantamab page is used to inform the browser and visitors of the page about the general meta information. The head section of the page is where we place the page title, the definition of the HTML version used, the language of in which the page is written. In the head section we can also include JavaScript and CSS (markup) files for the page.
Page title
Title length
amivantamab wikipedia
Meta description
Meta description legth
Meta description SEO
No meta relevance in the description detected !
Content SEO
Number of Words
Spam detected?
Headings
Heading distribution
Heading normalisation
Heading SEO impact
Emphasis (bold and italic)
Emphasis SEO impact
Images
Number of images
Images dimensions
Image alt descriptions
Images SEO impact
wikipedia free encyclopedia public domain icon wikimedia foundation powered mediawiki
Mobile SEO en.wikipedia.org/wiki/amivantamab
Mobile rendering
Mobile optimizations
Responsive design detected (mobile css)
No flash detected !
Mobile improvement
Marketing / lead generation for en.wikipedia.org/wiki/amivantamab
Social Media
Facebook shares | Facebook likes | ||
Facebook comments | Tweets | ||
Google +1 |
Conversion form
Search form
Analytics
Online presence
SERP Preview
SERP Title
SERP Link
SERP Description
Domain Level SEO
Domain name
16 characters long
Domain name SEO Impact
Path name
amivantamab found in path !
Structured data
Publisher Markup
Other Structured data
Website configuration
Correct processing of non-existing pages?
Favicon icon found?
Robots.txt found?
Sitemap found?
Navigation and internal links
Navigation
Url seperator
Human readable urls
Number of links
Link SEO Impact
statistics
|
en.m.wikipedia.org |
en.wikipedia.org wikimedia foundation inc
|
w view history
httpsenwikipediaorgwindexphptitleamivantamaboldid1246776266
page information
printable version
botensilimab
angiopoietin 3
depatuxizumab
trastuzumab duocarmazine
5 tomoregulin tmeff
aprutumab ixadotin
telisotuzumab
glypromate gpe 13igf1
evt901 sar127963
abt110 pg110
levi04 p75ntrfc
gambogic amide
sna120 pegylated k252a
ren1820 trkad5
|
wiki read
monoclonal antibodies
human
target
egferbb1her1
mesenchymalepithelial transition
trade names
drugscom
medlineplus
legal status
dailymed
pregnancycategory
routes ofadministration
intravenous infusion
drug class
antineoplastic agents
l01
only
cas number
drugbank
kegg
formula
molar mass
bispecific monoclonal antibody
nonsmall cell lung cancer
egf urogastrone
food and drug administration
firstinclass medication
indicated
carboplatin
pemetrexed
lazertinib
nonsmallcell lung cancer
committee for medicinal products for human use
european medicines agency
international nonproprietary name
osimertinib
public domain
pmid
world health organization
public domain material
clinicaltrialsgov
targeted cancer therapy
monoclonal antibodies
receptor tyrosine kinase
erbb
cetuximab
panitumumab
erbb2her2
pertuzumab
trastuzumab
hyaluronidase
trastuzumab emtansine
trastuzumab deruxtecan
epcam
catumaxomab
edrecolomab
bevacizumab
leukemia
lymphoma
lymphoid
glofitamab
elranatamab
mosunetuzumab
cd20
ibritumomab tiuxetan
obinutuzumab
ofatumumab
rituximab
tositumomab
cd30
brentuximab vedotin
cd52
alemtuzumab
myeloid
cd33
gemtuzumab ozogamicin
atezolizumab
hyaluronidase
avelumab
axatilimab
belantamab mafodotin
bermekimab
blinatumomab
cemiplimab
daratumumab
dinutuximab beta
dostarlimab
durvalumab
elotuzumab
enfortumab vedotin
epcoritamab
inotuzumab ozogamicin
ipilimumab
isatuximab
loncastuximab tesirine
mirvetuximab soravtansine
mogamulizumab
moxetumomab pasudotox
naxitamab
necitumumab
nivolumab
olaratumab
oportuzumab monatox
pembrolizumab
polatuzumab vedotin
ramucirumab
retifanlimab
sacituzumab govitecan
serplulimab
sugemalimab
tafasitamab
talquetamab
tarlatamab
teclistamab
tislelizumab
tisotumab vedotin
toripalimab
tremelimumab
tyrosine kinase inhibitors
afatinib
aumolertinib
brigatinib
dacomitinib
erlotinib
gefitinib
icotinib
mobocertinib
olmutinib
rociletinib
vandetanib
lapatinib
neratinib
tucatinib
rtk class iii
scf ckit
avapritinib
axitinib
masitinib
pazopanib
ripretinib
sorafenib
sunitinib
toceranib
flt3
lestaurtinib
gilteritinib
vegfr
cediranib
fruquintinib
lenvatinib
nintedanib
regorafenib
semaxanib
tivozanib
alectinib
ceritinib
ret gfl
entrectinib
futibatinib
infigratinib
larotrectinib
pemigatinib
pralsetinib
repotrectinib
selpercatinib
cmet
cabozantinib
capmatinib
crizotinib
nonreceptor
bcrabl
asciminib
bosutinib
dasatinib
imatinib
nilotinib
ponatinib
radotinib
src
janus kinase
baricitinib
fedratinib
filgotinib
momelotinib
pacritinib
ruxolitinib
binimetinib
cobimetinib
selumetinib
trametinib
eml4
lorlatinib
brutons
acalabrutinib
ibrutinib
orelabrutinib
pirtobrutinib
zanubrutinib
fusion protein
aflibercept
proapoptotic
anxa2
prohibitin
adipotide
exotoxin
il2
denileukin diftitox
mtor inhibitors
everolimus
ridaforolimus
temsirolimus
hedgehog
glasdegib
sonidegib
vismodegib
cdk inhibitors
abemaciclib
dalpiciclib
palbociclib
ribociclib
trilaciclib
kras
adagrasib
sotorasib
pi3k inhibitors
alpelisib
copanlisib
duvelisib
idelalisib
parsaclisib
erdafitinib
midostaurin
odronextamab
pexidartinib
quizartinib
tebentafusp
tepotinib
venetoclax
tumor
adecatumumab
ascrinvacumab
cixutumumab
conatumumab
drozitumab
duligotumab
dusigitumab
enoticumab
figitumumab
flanvotumab
ganitumab
glembatumumab vedotin
intetumumab
iratumumab
istiratumab
icrucumab
lexatumumab
lucatumumab
mapatumumab
narnatumab
nesvacumab
patritumab
pritumumab
radretumab
rilotumumab
robatumumab
seribantumab
tarextumab
teprotumumab
tovetumab
vantictumab
votumumab
zalutumumab
abagovomab
altumomab pentetate
anatumomab mafenatox
arcitumomab
bectumomab
capromab pendetide
detumomab
igovomab
lilotomab
minretumomab
mitumomab
nacolomab tafenatox
naptumomab estafenatox
oregovomab
pemtumomab
racotumomab
satumomab pendetide
solitomab
taplitumomab paptox
nofetumomab merpentan
pintumomab
tenatumomab
chimeric
amatuximab
bavituximab
carotuximab
derlotuximab biotin
dinutuximab
ecromeximab
ensituximab
futuximab
girentuximab
indatuximab ravtansine
margetuximab
siltuximab
ublituximab
zolbetuximab
humanized
abituzumab
bivatuzumab mertansine
brontictuzumab
cantuzumab mertansine
cantuzumab ravtansine
cirmtuzumab
citatuzumab bogatox
clivatuzumab tetraxetan
cofetuzumab pelidotin
dacetuzumab
demcizumab
dalotuzumab
denintuzumab mafodotin
emactuzumab
emibetuzumab
enoblituzumab
etaracizumab
farletuzumab
ficlatuzumab
flotetuzumab
imgatuzumab
labetuzumab
lifastuzumab vedotin
lintuzumab
lorvotuzumab mertansine
lumretuzumab
matuzumab
milatuzumab
nimotuzumab
ocaratuzumab
otlertuzumab
onartuzumab
parsatuzumab
pinatuzumab vedotin
rosmantuzumab
rovalpituzumab tesirine
sibrotuzumab
simtuzumab
sofituzumab vedotin
tacatuzumab tetraxetan
tigatuzumab
tucotuzumab celmoleukin
vandortuzumab vedotin
vanucizumab
veltuzumab
vorsetuzumab mafodotin
ratmouse hybrid
ertumaxomab
depatuxizumab mafodotin
duvortuxizumab
ontuxizumab
withdrawn
clinical trials
phase iii
growth factor receptor
modulators
angiopoietin
angiopoietin 1
angiopoietin 4
angiopoietin 2
rebastinib
evinacumab
axokine
amphiregulin
betacellulin
epigen
epiregulin
heparinbinding egflike growth factor hbegf
murodermin
nepidermin
transforming growth factor alpha tgf
canertinib
grandinin
mubritinib
erbb3her3
neuregulins heregulins
2
6 neuroglycan c
erbb4her4
3
4
1
2 bfgf
3
4
5
6
8
10 kgf2
20
trafermin
7
9
17
18
22
palifermin
sprifermin
23
burosumab
19
fgf1519
hgf cmet
fosgonimeton
hepatocyte growth factor
dihexa pnb0408
foretinib
k252a
tivantinib
volitinib
telisotuzumab vedotin
des13igf1
insulinlike growth factor1 somatomedin c
igf1 lr3
insulinlike growth factor2 somatomedin a
insulin
mecasermin
mecasermin rinfabate
linsitinib
1
2
3
4
5
6
7
trofinetide
lngf p75ntr
bnn20
bnn27
cenegermin
nt3
nt4
dexamethasone
testosterone
fasinumab
frunevetmab
fulranumab
tanezumab
becaplermin
plateletderived growth factor
a
b
c
d
crenolanib
motesanib
gfr1
glial cell linederived neurotrophic factor gdnf
gfr2
neurturin nrtn
gfr3
artemin artn
gfr4
persephin pspn
ancestim
stem cell factor
trk
trka
amitriptyline
tavilermide
fx007
trkb
4dma78dhf
78dhf
783thf
deoxygedunin
deprenyl
diosmetin
hioc
lm22a4
nacetylserotonin
norwogonin 578thf
r7
r13
ana12
cyclotraxin b
gossypetin 357834hhf
trkc
placental growth factor pgf
pegaptanib
alacizumab pegol
ranibizumab
adrenomedullin
colonystimulating factors
connective tissue growth factor ctgf
ephrins
a1
a2
a3
a4
a5
b1
b2
b3
erythropoietin
glucose6phosphate isomerase gpi pgi phi amf
glia maturation factor gmf
hepatomaderived growth factor hdgf
interleukins
tcell growth factors
leukemia inhibitory factor lif
macrophagestimulating protein msp hlp hgflp
midkine negf2
migrationstimulating factor msf prg4
oncomodulin
pituitary adenylate cyclaseactivating peptide pacap
pleiotrophin
renalase
thrombopoietin
wnt signaling proteins
cerebrolysin
|
Links to external pages
Outloing links
or.wikipedia.org
www.wikidata.org
www.drugs.com
www.medlineplus.gov
dailymed.nlm.nih.gov
www.whocc.no
commonchemistry.cas.org
www.drugbank.ca
precision.fda.gov
www.kegg.jp
www.tga.gov.au
www.ema.europa.eu
web.archive.org
www.globenewswire.com
www.fda.gov
www.fda.gov
www.janssen.com
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.ema.europa.eu
hdl.handle.net
www.doi.org
www.doi.org
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.businesswire.com
www.fda.gov
www.doi.org
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.clinicaltrials.gov
foundation.wikimedia.org
foundation.wikimedia.org
foundation.wikimedia.org
www.wikimediafoundation.org
SEO Advice for en.wikipedia.org
In this section we provide pointers on how you can to optimize your web page so it can be found more easily by search engines and how to make it rank higher by optimizing the content of the page itself. For each of the individual criteria the maximum score is 100%. A score below 70% is considered to be indication that the page is not complying with general SEO standards and should be evaluated and/or fixed. Not every factor is weighted the same and some are not as important as others. Relatively unimportant factors like meta keywords are not included in the overall score.
Item | Factor | Pointers | |
---|---|---|---|
PageTitle | 100% | Far too many sites lack a page title. A page title is the first thing that shows in the search results so always use the title element. | |
Title relevance | 65% | A title should reflect the contents of a site. This site has a 50 % match | |
Title Length | 30% | Limit your title to anywhere between 40 and 70 characters. Your title was 24 characters long | |
Meta Description | 0% | A meta description is the second element that shows in the search results so always use the meta description. | |
Meta description length | 0% | The meta description should be between 145 and 160 characters. This meta description is 1 characters long. | |
Meta description relevance | 0% | Meta Description should reflect the contents of a site. This site has a 0 % match | |
Number of internal links | 30% | Linking to internal pages makes pages easier to find for search engines. Try to keep the number of links on your page roughly below 100. There are 988 internal links on this page. | |
Folder structure | 100% | We found a folder structure in the links on your page. A good folder structure makes a site easier to navigate. We found 3 level 1 folders and 10 folders above or in the first level of navigation. | |
Headings | 14% | Headers should reflect the contents of a site. This site has a 6 % match | |
Links | 8% | Link anchors should to some degree reflect the contents of a site. This site has a 4 % match | |
Image alt tags | 0% | Image alt tags should to some degree reflect the contents of a site. This site has a 0 % match | |
Bold and italic | 60% | Bold and italic tags should reflect the contents of a site to some degree. This site has a 20 % match | |
Html ratio | 30% | Try to keep the html / text ratio as low as possible. More html means longer loading times. Layout should be handled in a serpate css file | |
Image descriptions | 86% | 85.714285714286 % of all images have been described via the "alt" attribute. Describing images with relevant text may lead to better results in the search engines. | |
Page errors | 100% | Pages with no errors display significantly faster on most browsers. We detected 0 errors and warnings | |
WordCount | 20% | An ideal page contains between 400 and 600 words.This page contains 3263 words | |
Server response time | 100% | A fast server speeds up a website. This server responds 93.93% faster then average | |
Gzip compression | 30% | This site does not use Gzip compression. Pages may not display as fast as they could | |
Keywords in Domainname | 30% | There are no important keywords in your domain name | |
Keywords in domain path | 100% | There are important keywords in the domain path | |
Structured Data | 100% | Structured data makes it easier for search engines to index your website | |
Inline css | 0% | Do not use inline css declarations. Inline css will slow down the rendering of the website. We detected 199 inline style declarations ( <a style="color:green">) with a size of 3881 bytes | |
Excessive use of the same words | 100% | There is no indication that there are one or more keywords that are used excessively. | |
Frames or iframes | 100% | Perfect, detected not (i)frames on your webpagina | |
Flash | 100% | Perfect, we detected no flash objects on your page | |
Css | 30% | We detected too much (2) CSS files on your page. Css files block the loading of a webpage. | |
Javascript | 100% | Perfect, we did not detect too many blocking JavaScript files | |
Mobile Website | 100% | Perfect, we found a responsive design for mobile users | |
Most important heading | 100% | Perfect, we detected a correct use of the most important (h1) heading! | |
Normalized headings | 40% | We dit not font a normalized heading structure. A heading 2 (h2) for example should be followed by a heading of an equal level (h2), a child heading (h3) or even a aprent heading (h1). |
How would you like to have SEO advice for all your pages ?? Start your SEO Dashboard and optimize your website!
en.wikipedia.org images and descriptions
8 images found at en.wikipedia.org Images can improve the user experience for a website by making a pag visually appealing Images can also add extra keyword relevance to a webpage by using alt tags. Images can also slow down a website. If the width and height for a picture is not specified for a browser know in advance how large the image is. A browser must first load the picture and see before it knows how much space should be on the page. Upon reservation In the meantime, the browser can do little but wait. When the height and width for the plate are given in the HTML code, a browser just continues to build for a page while the images load in the background.
http://en.wikipedia.org/static/images/icons/wikipedia.png height: 50 width: 50 description: no alt description found |
|
http://en.wikipedia.org/static/images/mobile/copyright/wikipedia-wordmark-en.svg height: height attribute not set width: width attribute not set description: wikipedia |
|
http://en.wikipedia.org/static/images/mobile/copyright/wikipedia-tagline-en.svg height: 13 width: 117 description: the free encyclopedia |
|
https://upload.wikimedia.org/wikipedia/en/thumb/6/62/pd-icon.svg/12px-pd-icon.svg.png height: 12 width: 12 description: public domain |
|
https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/who_rod.svg/8px-who_rod.svg.png height: 19 width: 8 description: icon |
|
https://login.wikimedia.org/wiki/special:centralautologin/start?type=1x1 height: 1 width: 1 description: no alt description found |
|
http://en.wikipedia.org/static/images/footer/wikimedia-button.svg height: 29 width: 84 description: wikimedia foundation |
|
http://en.wikipedia.org/w/resources/assets/poweredby_mediawiki.svg height: 31 width: 88 description: powered by mediawiki |
How are images contributing to your SEO site-wise ? Your leading content tool has the awnsers!